Advertisement
Table 1 Comparison of baseline characteristics between PDAC patients in the OPD and LPD groups
| Characteristic | Original cohort | P | Matched cohort | P | ||
|---|---|---|---|---|---|---|
| OPD group | LPD group | OPD group | LPD group | |||
| Total (cases) | 230 | 79 | 93 | 55 | ||
| Age [years, median (IQR)] | 64.0 (57.0–69.3) | 64.0 (56.0–70.0) | 0.817 | 64.0 (59.0–70.5) | 63.0 (54.0–69.0) | 0.337 |
| Gender [cases (%)] | 0.027 | 0.959 | ||||
| Male | 140 (60.9) | 59 (74.7) | 68 (73.1) | 40 (72.7) | ||
| Female | 90 (39.1) | 20 (25.3) | 25 (26.9) | 15 (27.3) | ||
| BMI [kg/m2, median (IQR)] | 22.5 (20.5–24.2) | 23.2 (20.7–25.3) | 0.100 | 22.3 (20.3–23.9) | 23.0 (20.7–25.2) | 0.107 |
| ASA score [cases (%)] | 0.059 | 0.149 | ||||
| 1 | 43 (18.7) | 6 (7.6) | 18 (19.4) | 5 (9.1) | ||
| 2 | 177 (77.0) | 68 (86.1) | 73 (78.5) | 47 (85.5) | ||
| 3 | 10 (4.3) | 5 (6.3) | 2 (2.2) | 3 (5.5) | ||
| Charlson comorbidity index [cases (%)] | 0.324 | 0.356 | ||||
| 0 | 144 (62.6) | 44 (55.7) | 58 (62.4) | 31 (56.4) | ||
| 1 | 64 (27.8) | 29 (36.7) | 28 (30.1) | 22 (40.0) | ||
| ≥ 2 | 22 (9.6) | 6 (7.6) | 7 (7.5) | 2 (3.6) | ||
| Year of operation [cases (%)] | 0.256 | 0.447 | ||||
| 2013–2015 | 114 (49.6) | 45 (57.0) | 55 (59.1) | 29 (52.7) | ||
| 2016–2017 | 116 (50.4) | 34 (43.0) | 38 (40.9) | 26 (47.3) | ||
| Tumor differentiation [cases (%)] | 0.006 | 0.421 | ||||
| Well-moderate | 82 (35.7) | 42 (53.2) | 41 (44.1) | 28 (50.9) | ||
| Poor | 148 (64.3) | 37 (46.8) | 52 (55.9) | 27 (49.1) | ||
| Nerve invasion [cases (%)] | < 0.001 | 0.131 | ||||
| Yes | 203 (88.3) | 44 (55.7) | 73 (78.5) | 37 (67.3) | ||
| No | 27 (11.7) | 35 (44.3) | 20 (21.5) | 18 (32.7) | ||
| T stage [cases (%)] | 0.001 | 0.835 | ||||
| 1 | 61 (26.5) | 12 (15.2) | 15 (16.1) | 10 (18.2) | ||
| 2 | 158 (68.7) | 54 (68.4) | 73 (78.5) | 41 (74.5) | ||
| 3 | 11 (4.8) | 13 (16.5) | 5 (5.4) | 4 (7.3) | ||
| N stage [cases (%)] | 0.942 | 0.886 | ||||
| 0 | 123 (53.5) | 44 (55.7) | 50 (53.8) | 32 (58.2) | ||
| 1 | 86 (37.4) | 28 (35.4) | 35 (37.6) | 19 (34.5) | ||
| 2 | 21 (9.1) | 7 (8.9) | 8 (8.6) | 4 (7.3) | ||
| AJCC TNM stage [cases (%)] | 0.794 | 0.831 | ||||
| I | 117 (50.9) | 37 (46.8) | 46 (49.5) | 30 (54.5) | ||
| II | 92 (40.0) | 35 (44.3) | 39 (41.9) | 21 (38.2) | ||
| III | 21 (9.1) | 7 (8.9) | 8 (8.6) | 4 (7.3) | ||
| Adjuvant treatment [cases (%)] | < 0.001 | 0.701 | ||||
| Yes | 162 (70.4) | 31 (39.2) | 47 (50.5) | 26 (47.3) | ||
| No | 68 (29.6) | 48 (60.8) | 46 (49.5) | 29 (52.7) | ||
